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The COVID-19 pandemic and the social unrest pervading US cities in response to the killings of 
George Floyd and other Black citizens at the hands of police are historically significant. These 
events exemplify dismaying truths about race and equality in the United States. Racial health 
disparities are an inexcusable lesion on the US healthcare system. Many health disparities 
involve medications, including antidepressants, anticoagulants, diabetes medications, drugs for 
dementia and statins, to name a few. Managed Care Pharmacy has a role in perpetuating racial 
disparities in medication use. For example, pharmacy benefit designs are increasingly shifting 
costs of expensive medications to patients, creating affordability crises for lower income 
workers, who are disproportionally persons of color. Additionally, the quest to maximize 
rebates serves to inflate list prices paid by the uninsured, among which Black and Hispanic 
people are over-represented. While medication cost is a foremost barrier for many patients, 
other factors also propagate racial disparities in medication use. Even when cost-sharing is 
minimal or zero, medication adherence rates have been documented to be lower among Blacks 
as compared with Whites. Deeper understandings are needed about how racial disparities in 
medication use are influenced by factors such as culture, provider bias, and patient trust in 
medical advice. Managed Care Pharmacy can address racial disparities in medication use in 
several ways. First, it should be acknowledged that racial disparities in medication use are 
pervasive and must be resolved urgently.  We must not believe that entrenched health-system, 
societal and political structures are impermeable to change. Second, the voices of community 
members and their advocates must be amplified. Coverage policies, program designs, and 
quality initiatives should be developed in consultation with those directly impacted by racial 
disparities. Third, the industry should commit to dramatically reducing patient cost sharing for 
essential medication therapies. Federal and state efforts to limit annual out-of-pocket 
pharmacy spending should be supported, even though increased premiums may be an 
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undesirable (yet more equitable) consequence. Finally, information about race should be 






The COVID-19 pandemic and the social unrest pervading US cities in response to the killings of 
George Floyd and other persons of color exemplify dismaying truths about race and equality in 
the United States. Rates of SARS-CoV-2 infection and hospitalizations have been higher among 
Blacks than for Whites, and Blacks have been more than twice as likely to die to from COVID-
19.1,2 These disparities mirror other health inequities among Blacks in the US, including higher 
rates of being uninsured,3 higher infant4 and maternal5 mortality, poorer health outcomes of 
chronic disease,6-8 and diminished life expectancy overall.9 These troubling realities 
undoubtedly add to the passion and anger expressed by the millions of protesters that took to 
our nation’s streets. Their voices urge us all to reflect on our roles in perpetuating inequities, 
whether active or passive, and to commit in both spirit and action to advance change.  
 
On June 18, 2020 the Academy of Managed Care Pharmacy issued a statement entitled AMCP 
Stands Against Racial Injustice, stating that “we felt this letter was a crucial step for AMCP to 
take in the fight against racism and inequality.”10 In contributing this unsolicited Viewpoint 
article, I intend to add to AMCP’s statement by providing additional context and opinion, and 
offering recommendations for action.  I am a long-standing AMCP member and a former 
member of the JMCP Editorial Advisory Board (EAB). However, the views expressed in this 
article are my own, and were developed without any consultation from AMCP leadership or 
EAB members. Additionally, this article predominantly addresses disparities involving Black and 
Hispanic Americans, yet the issues and recommendations discussed extend to other groups 




In 1966, Dr. Martin Luther King Jr., in remarks associated with the Second National Convention 
of the Medical Committee for Human Rights, stated that “Of all the forms of inequality, 
injustice in health care is the most shocking and inhumane.”11  In the ensuing years the US 
Health and Human Services (HHS) has endeavored to respond. Racial disparities were detailed 
in a landmark report of the Secretary's Task Force on Black and Minority Healthy in 1985,12 
which led to the creation of the HHS Office of Minority Health (OMH). More recently, in 2011 
HHS issued an Action Plan to Reduce Racial and Ethnic Health Disparities,13 which included 
priorities, goals and strategies to address “deeply rooted disparities that have defied major 
efforts toward progress for years.” The US Assistant Secretary for Planning and Evaluation 
published a progress report on this Action Plan in November, 2015,14 which described activities 
by federal agencies to address barriers and promote equity in health and health care. Also in 
2015, the OMH provided its biennial progress report on disparities to Congress, as required by 
the Affordable Care Act (ACA).  The OMH under the Trump Administration has not provided 
these required reports for 2017 or 2019.15   Also notable is the Institute of Medicine’s 2003 
report entitled Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care,16 
which included specific examples of racial disparities in prescription medication use. 
Additionally, the US Agency for Healthcare Research issues annual reports of healthcare quality 
and disparities that include comparisons across racial groups.17 Despite these efforts, racial 
health disparities remain as an inexcusable a lesion on the US healthcare system. 
 
Health disparities often involve medications, as prescription drug therapies are fundamental to 
basic health care. Managed Care Pharmacy promotes “A structured approach to financing and 
delivering covered health care benefits designed to provide affordable access to improve the 
quality of care in a cost-effective manner.”18 Not explicitly stated in this definition, though 
assumedly implied, is the aim to provide affordable access and quality for all.  Is Managed Care 
Pharmacy living up to this ideal?  Racial disparities have been documented in the utilization of 
essential evidence-based drug therapies, including antidepressants,19 anticoagulants,20 diabetes 
medications,21 drugs for dementia,22 and statins,23 to name a few. Racial or ethnic disparities in 
medication use have been associated with the failure to achieve therapeutic goals, increased 
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rates of hospitalization, and decreased survival.24 Pharmacists have responded with initiatives 
to address disparities in medication use among underserved and vulnerable populations, more 
recently with heightened focus on the social determinants of health.25  However, medication 
cost remains a formidable barrier to closing the disparities gap in medication use between 
Blacks and Whites, including both the uninsured and those having a pharmacy benefit.  
 
Black and Hispanic people in the US earn less than Whites. According to the U.S Bureau of Labor 
Statistics, the median weekly full-time pay for Whites in 2018 was $916, contrasted with $694 
for Blacks and $680 for Hispanic workers.26 Hispanic  and Blacks are also more likely to be paid 
poverty-level wages than Whites.27 Therefore, out-of-pocket prescription drug payments 
consume a higher percentage of the earnings of these groups, who may prioritize paying rent or 
obtaining food as a necessary trade-off.28-31 Patient cost sharing within the modern pharmacy 
benefit is often quite low. The average patient out of pocket contribution for a prescription 
medication in 2019 was $10.34,32 which is less than half of the average price for a prescription 
medication nearly 30 years ago ($22.06 in 1990) when more than half of prescriptions were 
paid for using cash.33 However, this comparison does not address prices paid by today’s 
patients who lack health insurance, or the deviation in patient out-of-pocket spending 
associated with current pharmacy benefit designs.  
 
Today’s low average out-of-pocket prescription costs are driven by the increasing array of 
generic medications used in the management of prevalent chronic diseases. Examining patient 
out-of-pocket payments for brand name medications, and specialty medications in particular, 
reveals a different story. According to a report by the IQVIA Institute for Human Data Science 
on prescription drug spending and affordability, approximately 10% of brand name 
prescriptions in commercial and Medicare Part D plans required an out-of-pocket cost of $50 or 
more in 2019.32 Moreover, the most frequent high-cost claims (> $125)  were for medications 
indicated for diseases that disproportionally affect Blacks, including diabetes,34,35 HIV,36 
obesity,37 respiratory disease,38,39 and stroke.40,41 The Medicare Part D benefit design also 
exposes patients to extremely high out-of-pocket costs. Yearly patient copayments for guideline 
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recommended medications for cancer can exceed $10,000 under the Medicare Part D design.42 
In the commercial sector, for benefits sponsored by large employers, more than half of designs 
with a tier for specialty drugs require coinsurance.43 Other trends in pharmacy benefit design 
include rising deductibles, and for high-deductible health plans, coinsurance within all tiers.43  
 
Pharmacy benefit designs can pour salt on the wounds of those affected by disparities, parsing 
patients into the haves and have nots. Concerns about the impact of increased pharmacy cost 
sharing on medication access are not a new phenomenon,44-46 and approximately 24% of 
insured low-income Americans reported skipping medications or doses due to cost in 2016.47  
This exemplifies a shortcoming of unbridled capitalism in health care.48 While market forces can 
drive innovation and empower thriving systems for healthcare service delivery, perfectly 
competitive markets allocate goods and services according to the consumer’s (patient’s) 
willingness and ability to pay.  As wealth and race are correlated,49 pharmacy cost-sharing is 
therefore not only an issue of patient affordability but also a matter of racial justice.  
 
While the average per capita out-of-pocket spending for medications is not dramatically higher 
in the US, other nations’ systems provide more protection against the highest levels of out of 
pocket spending.47  Many in the US are at the peril of financial ruin should they develop a 
disease that requires an expensive therapeutic. Indeed, more than half of US bankruptcies have 
a medical origin, and most filers had health insurance.50 Disparities also exist in rates of accrued 
medical expenses, with Blacks being more than twice as likely than Whites to compile medical 
debt.51 
 
Racial disparities in medication access among the uninsured 
 
The Managed Care Pharmacy community must elevate its advocacy for the uninsured, who face 
substantial economic barriers in accessing medication. While racial disparities in health 
insurance coverage have improved since the passage of the ACA,52 these gains are threatened 
by the law’s uncertain future. Among non-elderly adults, 14.4% of Blacks and 24.9% of Hispanic 
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people nationally lacked health insurance in 2018, compared with only 8.6% of Whites.53 
Uninsured individuals paid an average cash price of $43.67 for a generic prescription, and 
$105.74 for a brand name prescription in 2019.32 Prices have been driven higher by the push for 
steeper rebates, placing upward pressure on drug list prices to yield greater discounts.54 Hence, 
rebate savings accrue to covered populations, at the expense of those lacking coverage, among 
which approximately half are persons of color.55 
 
The Managed Care Pharmacy community should consider medication access for the uninsured 
to be a concern within its domain. Many of the uninsured were recently insured, and may be 
insured again. Data from the National Health Interview Survey for 2018 reveal that among the 
non-elderly uninsured, 21% had recently lost or changed their job, while 13% recently lost 
eligibility for Medicaid.56 More must be done to aid those who are transitioning out of having 
prescription drug coverage. It might prove to be cost-effective to subsidize medication costs for 
the temporarily uninsured, rather than to later incur claims for disease complications.  We 
should strive to overcome the system fragmentation that disincentivizes such an approach. 
Aside from the business case, from an ethical perspective in my view it is shameful that we 
allow so many low-income Americans to be uninsured and without access to prescription drug 
coverage, while subsidizing prescription medication costs for all Part D beneficiaries, 
irrespective of their wealth. Therein lies the power of advocacy, which must now be leveraged 
to eliminate racial disparities in medication use among the insured and uninsured alike.   
 
Health systems have been tasked with responding to the health-related needs of the 
community. Examples include Medicare’s Accountable Health Communities model, and the 
ACA-mandated community health needs assessment reports that are required of non-profit 
hospitals.57,58  Moreover, there is a growing recognition of the critical need to more fully and 
effectively engage community stakeholders to improve clinical care and enhance health system 
designs. In their paper entitled Transitioning from Learning Healthcare Systems to Learning 
Health Care Communities, Mullins et al write: “…the greatest disparities between low and high 
income patients as relates to differences in the degree of engagement with the health system 
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and providers are seen in the USA.”59 Accordingly, those in Managed Care Pharmacy must 
increasingly engage community stakeholders in efforts to devise and implement strategies that 
reduce racial disparities in medication use.  These efforts must be deliberate, prioritized and 
sustained.  
 
It’s not only about cost 
 
While medication cost is a foremost barrier for many patients, other factors propagate racial 
disparities in medication use. Even when cost-sharing is minimal or zero, such as in Medicaid 
pharmacy programs, medication adherence rates have been documented to be lower among 
Blacks as compared with Whites.60-63  Deeper understandings are needed of how medication-
related disparities are influenced by factors such as culture, provider bias, and trust in medical 
advice. Much can be learned by listening to members of communities affected by health 
disparities, as noted above. Moreover, Managed Care Pharmacy professionals must heighten 
collaborations with other health system professionals who serve those who are subjected to 
racial disparities. These workers include nurses, community health workers, clinical social 
workers, and community health center administrators, among others.  
 
What about the drug manufacturers? 
 
There is an elephant in the room yet to be addressed: medication prices. I am optimistic that 
Managed Care Pharmacy will have a major role in transitioning drug payment models away 
from volume-driven rebates towards value-based arrangements that recognize innovation and 
superior outcomes. Manufacturers should provide discounts or returned funds when the 
purported outcomes of a medication therapy are not fully realized, and these arrangements 
should include evaluating outcomes among racial groups. The data tracking required by value-
based payment arrangements provides the impetus to more formally incorporate data on race, 
socioeconomic status, and social determinants of health when measuring key performance 
indicators. Additionally, Pharmacy and Therapeutics committees should demand that dossiers 
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for new drugs contain information about the impacts of a new drug on health disparities. This 
might include incorporating details of known health disparities for the condition of interest, and 
describing barriers to treatment access that may affect vulnerable groups..  
 
There are also implications for pharmacoeconomic data.  It is encouraging that cost-
effectiveness analyses (CEAs) are increasingly used by Managed Care Pharmacy decision-
makers in pricing negotiations.64  Yet these economic analyses typically consider a long 
timeframe of therapy, and assess cost from the perspective of the health system, not the 
patient. While the CEAs for many specialty drugs purport cost-effectiveness according to 
predefined thresholds, many such medications require extremely high patient cost sharing. 
Cost-effectiveness is not a measure of affordability. Yet cost-effectiveness analysis should not 
be eschewed as irrelevant to disparities; indeed, its application can optimize spending over the 
long run, enabling resources to be redirected to reduce patient cost sharing.  
     
There is also a potential role for CEAs in evaluating the trade-offs in foregoing newer higher-
priced medications in favor of “tried and true” lower cost agents. Such studies would seem to 
be particularly salient for therapeutic areas where newer drugs are supplanting older evidence-
based medications, such as in diabetes, mental health illnesses, and some types of cancer.  A 
better understanding of these trade-offs would inform efforts to optimize program resources, 
while potentially substantially reducing patient out-of-pocket expenditures. This is not to 
suggest that some patients would be relegated to receive inferior medications. Rather, when 
making a difficult choice between purchasing an expensive new medication, or obtaining food 
or paying rent, it would be helpful for patients to know how much potential health benefit 
would be foregone by selecting a next-best therapy that doesn’t involve the same magnitude of 
financial strain.  
 
Suggestions for action 
The Managed Care Pharmacy community can help to eliminate racial disparities in medication 
use in several ways. First, it should be formally acknowledged that racial disparities in 
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medication use are pervasive and must be resolved urgently. One must not believe that 
entrenched health-system, societal and political structures are impermeable to change. Second, 
the voices of community members and their advocates must be amplified. Coverage policies, 
program designs, and quality initiatives should be developed in consultation with those directly 
impacted by racial disparities. Third, Managed Care Pharmacy should commit to dramatically 
reduce patient cost sharing for essential medication therapies, for both insured and uninsured 
populations. Federal and state efforts to limit annual out-of-pocket pharmacy spending should 
be supported, even though increased premiums may be an undesirable (yet more equitable) 
consequence. Finally, information about race should be incorporated into all internal and 
external reporting and quality improvement activities. As the adage goes, “If you can’t measure 
it, you can’t improve it.”65  Relatedly, managed care and pharmacy journal requirements should 
specify that researchers include race as a covariate whenever possible, and consider yearly 





Former United States Representative and civil rights leader John Lewis said that "When you see 
something that is not right, not just, not fair, you have a moral obligation to say something, to 
do something."66  The Managed Care Pharmacy community can do its part by resolving to do 
more to eliminate racial disparities in medication use. Black Lives Matter. 
 
 
Postscript: I hope that this essay will elicit responses from those who have been steadfastly 
working to address racial disparities in medication use. It is a failing of this article that I have 
not described the efforts of the many groups and individuals committed to this cause. We must 
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